Parainfluenza

Infectious Diseases
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ansun BioPharma
Ansun BioPharmaCA - San Diego
2 programs
2
DAS181 dry powder, formulation F02Phase 21 trial
DAS181-F02 Dry Powder in BulkPhase 21 trial
Active Trials
NCT01644877Completed111Est. Dec 2016
NCT01924793Completed23Est. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ansun BioPharmaDAS181 dry powder, formulation F02
Ansun BioPharmaDAS181-F02 Dry Powder in Bulk

Clinical Trials (2)

Total enrollment: 134 patients across 2 trials

NCT01644877Ansun BioPharmaDAS181 dry powder, formulation F02

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Start: Mar 2014Est. completion: Dec 2016111 patients
Phase 2Completed
NCT01924793Ansun BioPharmaDAS181-F02 Dry Powder in Bulk

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

Start: Aug 2013Est. completion: May 201723 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space